-nitro-L-arginine methyl ester (L-NAME), has been shown to produce symptoms similar to pre-eclampsia (i.e. elevated blood pressure, proteinuria and fetal growth retardation). After L-NAME infusion is initiated on day 17 or 18 of gestation, the blood pressure proceeds in a biphasic pattern (immediate rise, followed by a decline, then increasing again in the post-partum period). The blood pressure actually begins to rise prior to delivery on days 21-22, i.e. after progesterone withdrawal occurs, suggesting that these responses may be regulated by changes in steroid hormone concentrations during pregnancy. Therefore, we evaluated the effects of the different steroid hormones: progestins (progesterone, promegestone, Ievonorgestrel), antiprogestins (mifepristone), 17{J-oestradiol or androgens (testosterone, dihydrotestosterone) on systolic blood pressure in pregnant, non-pregnant female and normal male rats with and without L-NAME treatment and spontaneously hypertensive male rats. The animals received continuous infusions of L-NAME (150 mg/kg/day) or vehicle through osmotic mini-pumps and daily s.c. injections of steroid hormones. In pregnant rats the pump was inserted on day 17 or 18 of gestation and steroid hormone injections were started on the first day following delivery at term and continued daily until post-partum day 10. In non-pregnant female or male rats steroid hormone injections were initiated 5 days after the L-NAME pump was inserted. Systolic blood pressure was measured daily from the tail with a pneumatic tail-cuff device. R5020 (1.5 mg/kg/day) significantly attenuated the blood pressure elevation induced by L-NAME during the post-partum period. Similarly, it lowered blood pressure in L-NAME treated non-pregnant female rats or male rats. R5020 also lowered blood pressure in spontaneously hypertensive male rats. Progesterone (6 mg/kg/day) had similar effects on blood pressure in the post-partum period, although it also lowered the blood pressure in control animals. Interestingly, administration of two different doses of Ievonorgestrel (03 and 1.5 mg/kg/day) did not decrease the blood pressure in either L-NAME-infused rats or controls. Mifepristone (RU486, 30 mg/kg/day) further increased © European Society for Human Reproduction and Embryology blood pressure in L-NAME-treated rats post-partum. 17f$-oestradiol (30 ng/kg/day) had no effect on blood pressure in either L-NAME infused rats in the post-partum period or controls, whereas both testosterone (03 mg/kg/day) and dihydrotestosterone (0.3 mg/kg/day) significantly attenuated the blood pressure increase after L-NAME, while raising the blood pressure in vehicle-infused animals. These results suggest that the control of systemic blood pressure during pregnancy may be modulated by steroid hormones. Progesterone may be the steroid hormone with the major action on vascular tension during pregnancy.
Introduction
Nitric oxide (NO), a short-lived free radical gas synthesized from L-arginine, is believed to be a major mediator of many biological functions including those of the cardiovascular, nervous, reproductive, respiratory, gastrointestinal and immune systems (Moncada et ai, 1991) In the cardiovascular system, NO is thought to be responsible for endothelium-dependent vasodilatation (Vanhoutte et ai, 1986) and inhibition of platelet aggregation (Radomski et ai, 1987) . In vascular tissues, NO activates soluble guanylate cyclase leading to an increase in cyclic guanosine monophosphate (cGMP) which in turn results in smooth muscle relaxation (Feelisch and Noack, 1987) . Many studies show that inhibition of vascular NO results in vasoconstriction (Rees et al, 1990 ) while application of NO or NO donors produces vasodilatation (Vanderford et al, 1994) The data indicate that Ln-vivo suppression of NO produces sustained hypertension in both animals (Johnson and Freeman, 1992) and healthy human subjects (Haynes et ai, 1995) .
There is much evidence to suggest that the physiological vascular adaptation to pregnancy (increased blood volume, increased cardiac output and decreased vascular resistance) is accompanied by an increase in endogenous NO production (Weiner et al, 1994 , Nathan et al., 1995 and responsiveness of the vascular smooth muscle to NO (Nelson et ai, 1995) . The blunted pressor response to agonists during pregnancy may be at least partially mediated by NO (Molnar and Hertelendy, 1992) . Sunano et al. (1989) reported that the endothelialdependent relaxation in spontaneously hypertensive rats (SHRs) is impaired In addition, SHRs become normotensive during gestation, independent of prostaglandin synthesis (Ahokas et ai, 1991) The systems that regulate NO and other complex vascular control mechanisms during pregnancy are not completely understood. There seems to be some controversy as to whether the changes in vascular tone and diminished responsiveness to pressor agents during pregnancy are due to changes in steroid hormones. Recent reports indicate that oestrogen may up-regulate nitric oxide synthesis (Van Buren et al., 1992) while modulating the endodielium-dependent relaxation in vascular tissues (Miller et al., 1988) . Some studies also found a relationship between oestrogen and blood flow dynamics (Volterrani et al, 1995) . Although the effect of progesterone on blood vessels has been previously investigated in vascular tissues, clear-cut conclusions were not made (Miller and Vanhoutte, 1991) . On the other hand, previous studies from our group indicate that progesterone may regulate the cGMP effector system for relaxation in both the myometrium (Buhimschiefa/., 1995a) and blood vessels (Izumief al, 1993) . Several studies have demonstrated that pregnant rats treated with nitric oxide synthase inhibitors, such as N G -nitro-L-arginine methyl ester (L-NAME) or N G -nitro-L-arginine (L-NA), develop signs similar to pre-eclampsia, including hypertension, fetal growth retardation and proteinuria (Baylis et al, 1992; Molnar and Hertlendy, 1992; Yallampalli and Garfield, 1993; Buhimschi et al, 1995b) . Similar findings were reported in guinea pigs following L-NAME treatment (Chwalisz et al, 1994) . These studies indicate that preeclampsia may be a condition characterized by a deficiency in NO production. We found that the blood pressure changes in the L-NAME-treated rats show a consistent pattern during late pregnancy and early post-partum. An initial increase in blood pressure on day one after treatment is followed by a decrease to values similar to the control group on days 20 and 21 of pregnancy, followed by a rise that starts prior to labour and continues into the post-partum period. The transient hypertension we observed in pregnant rats contrasts with sustained hypertension observed in non-pregnant female and male rats (Tabrizchi and Triggle, 1992; Molnar et al, 1994 ). It appears therefore that the refractoriness reported with other blood pressure regulating mechanisms (i.e. angiotensin IT) during pregnancy remains operational in rats treated with L-NAME. We hypothesized that changes in steroid hormones are responsible for modulating blood pressure in L-NAME treated rats since the rise in blood pressure begins following progesterone withdrawal on days 21-22, when oestrogen concentrations are increasing (Puri and Garfield, 1982) .
The aim of the present study was: (i) to confirm that, in contrast to pregnant animals where the increase is only transient, nitric oxide blockade in non-pregnant female and male rats is followed by a sustained increase in blood pressure levels; (ii) to show that diis refractoriness to L-NAME treatment is specific to pregnancy but not to the post-partum period; (iii) to compare the effect of R5020, a 'pure' progesterone receptor agonist with a higher affinity to receptors than progesterone, on systolic blood pressure in L-NAME chronically-infused animals; and (iv) to examine the effects of other steroid hormones and anti-hormones (17p*-oestradiol, RU486, levonorgestrel, testosterone and dihydrotestosterone) on the elevated post-partum blood pressure levels in L-NAMEtreated animals versus controls in order to determine other possible interactions between sex steroid hormones and the vascular adaptation systems.
Materials and methods

Animals
Adult nulliparous pregnant rats (300-325 g body weight) were purchased from Haiian-Sprague-Dawley (Houston, Texas, USA) and were received in our animal facilities on day 16 of pregnancy (day 0 = day of positive sperm smear) All animals were given free access to food and water. Non-pregnant female rats (225-250 g body weight) at indeterminate stages of the oestrus cycle and male normotensive and hypertensive rats (spontaneously hypertensive rats: SHR, Harlan Sprague-Dawley) (300-325 g body weight) were also used. All procedures were approved by the Animal Care and Use Committee of the University of Texas Medical Branch, USA.
L-NAME infusion
Starting on day 17 or 18 of pregnancy, rats received infusions by means of osmotic minipumps of the specific nitnc oxide synthase inhibitor, L-NAME (Sigma, St. Louis, MI, USA), dissolved in sterile saline solutton, at a rate of 150 mg/kg/day. Osmotic minipumps (Model 2ML2; Alza, Palo Alto, CA, USA) were filled with vehicle with or without L-NAME and placed s.c. during halothane (Halocarbon Laboratories, North Augusta, SC, USA) anaesthesia. The pumps deliver the drug at a constant rate of 5 ul/h, for up to 14 days. Non-pregnant female rats and male rats were also infused with L-NAME in the same dosage.
Steroid treatments
The following drugs were used: R5020 (promegestone, 1.5 mg/kg/ day; Roussel-Uclaf, Paris, France), progesterone (6 mg/kg/day), levonorgestrel (two doses: 0.3 and 1.5 mg/kg/day), 17p-oestradiol (30 |ig/kg/day), testosterone (0.3 mg/kg/day), dihydrotestosterone (0.3 mg/kg/day) (all from Sigma, St. Louis, MO, USA) and RU486 (30 mg/kg/day) from Schering AG, Berlin, Germany. Steroid compounds were suspended in sesame oil and injected s.c. daily starting with the first or second day post-partum. Generally, we used doses of the steroids which corresponded to those used in several studies. All pregnant animals delivered on day 22 of gestation, the expected day of delivery and L-NAME did not change the time of delivery, a rinding consistent with previous observations (Yallampalli and Garfield, 1993) . In non-pregnant female or normal male rats, injections were started 5 days after the initiation of L-NAME infusion when a relatively stable level of blood pressure was reached. Control rats in all groups were managed similar to the treated rats with the exception that the s.c. daily injections contained the vehicle only Blood pressure measurement Systolic blood pressure was measured with a pneumatic tail-cuff device (Narco-BioSystems, Houston, TX, USA) in animals that had been prewarmed in a metal chamber maintained at 30°C. The tailcuff method has been validated in numerous studies (Zatz, 1990) . Measurement of systolic blood pressure was carried out daily in all animals. Values obtained from three consecutive measurements were averaged and recorded as the pressure for a given rat at each point.
Statistical analysis
The data are presented as mean ± SEM. Statistical comparisons were performed between means obtained on each day using one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple comparison tests. A P value of 0.05 was considered as the limit for statistical significance. Figure 1 . Effect of N^nitro-L-arginine methyl ester (L-NAME) on systobc blood pressure of pregnant versus non-pregnant females or normal male rats. Blood pressure levels were measured on day 17 before the osmotic mirupumps were implanted s c , and then daily up to the 10th day post-pattum ipplO). Animals received 150 mg/kg/day L-NAME in saline solution (LN) or saline only (CRL). Each point in each of the final groups represents mean ± SEM from five male rats, eight non-pregnant or 13 pregnant female rats Figure 1 represents the daily systolic blood pressure recorded in pregnant, non-pregnant female and normal male rats treated with L-NAME (150 mg/kg/day) compared with control animals. In non-pregnant female and normal male rats the blood pressure rose slowly following L-NAME treatment to reach approximately 160 mm Hg after 5 days and 180 mm Hg after 7 days of L-NAME treatment. However, in pregnant rats infused with L-NAME from day 17 of gestation, the systolic blood pressure initially increased one day after the start of L-NAME, but then declined on days 19 to 21 to rise again before delivery. Post-partum, the pressure remained elevated and within the range for non-pregnant or male rats treated with L-NAME. Figure 2A shows the effect of R5020 in a dose of 1.5 mg/kg/ day on systolic blood pressure in post-partum rats exposed to L-NAME from day 17 of gestation to 10 days following delivery. Blood pressure was significantly reduced after R5020 administration in the L-NAME treated animals but not in the control rats. Similarly, R5020 significantly lowered the systolic blood pressure in L-NAME-treated non-pregnant female rats and normal male rats ( Figure 2B ,C), but did not reduce the blood pressure in non-hypertensive control rats infused with vehicle ( Figure 2A ,B,C). The blood pressure in male spontaneously hypertensive rats (SHRs) was also significantly reduced by R5020 ( Figure 2D ).
GestationaJ regulation of vascular tone
Days
Results
Effects of L-NAME
Effects of progestins and antiprogestins
Progesterone itself in a dose of 6 mg/kg/day lowered systolic blood pressure post-partum in L-NAME treated animals, but unlike R5020 also decreased blood pressure in control animals ( Figure 3A) . In contrast, the antiprogesterone RU486 (30 mg/ kg/day) significantly elevated blood pressure in post-partum L-NAME-treated rats as well as in control post-partum rats ( Figure 3B ).
Levonorgestrel (a progestagen, 19-nortestosterone derivative) at doses of 0.3 mg/kg/day ( Figure 4A ) or 1.5 mg/kg/day ( Figure 4B ) generally had no significant effect on blood pressure in L-NAME-treated animals in the post-partum period. However, the higher dose slightly elevated systolic blood pressure in control animals. Also, on the last day of blood pressure measurement (post-partum day 10) significantly lower values were recorded in the group receiving both L-NAME and levonorgestrel as compared with the group infused with L-NAME only.
Effects of np-oestradiol nP-Oestradiol (30 mg/kg/day) had no significant effect on blood pressure in post-partum control animals. After 7 days of daily injections, 17p-oestradiol administration significantly lowered the blood pressure in L-NAME-infused rats ( Figure  5 ) However, 17p-oestradiol had no effect on systolic blood pressure in SHR rats (data not shown)
Effects of androgens
Both testosterone (0.3 mg/kg/day) ( Figure 6A ) and dihydrotestosterone (0.3 mg/kg/day) ( Figure 6B ) significantly reduced blood pressure in post-partum L-NAME-infused rats, but significantly increased the blood pressure in control postpartum rats ( Figures 6A,B) .
Discussion
This study confirms previous findings of a rise in blood pressure in rats after L-NAME treatment (Buhimschi et al., 1995b) followed by a return to baseline and a prompt rise prior to delivery and in the post-partum period. This is in contrast to non-pregnant female and male rats where, after the initiation of the L-NAME infusion, blood pressure increases steadily and then is maintained at a high level (Figure 1 ) In addition, R5020, progesterone and androgens lower the increased blood pressure resulting from nitric oxide inhibition in the post-partum period. The effect of these hormones in control rats not treated with L-NAME was inconsistent While progesterone decreased it, androgens increased and R5020 had no effect on the blood pressure in control rats. R5020 had similar depressive effects in non-pregnant females, normal males and male SHRs. 17P-Oestradiol and levonorgestrel had little or no effect on the blood pressure. These findings indicate that sex steroids, which undergo major changes during pregnancy, have important effects on blood pressure and, therefore, may play significant roles in the regulation of vascular homeostasis in late pregnancy.
The initial rise in pressure occurs on the day following L-NAME treatment, persists for one day only and then rapidly returns to near the range for the untreated control pregnant rats. The day before the onset of labour, the blood pressure starts to increase again and remains elevated throughout the post-partum period This is in contrast to the sustained blood pressure elevation noted by other investigators in non-pregnant 
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Figure 2. Effect of R5020 (1.5 mg/kg/day) on systolic blood pressure in rats chronically infused with 150 mg/kg/day N°-nitro-L-arginine methyl ester (L-NAME) or saline alone. In pregnant rats (A) the osmotic minipumps were inserted 6 days pnor to R5020 or oil injections were started, on the first day post-partum (ppl). Non-pregnant female (B) and normal male rats (C) have been infused infused with L-NAME or saline for 5 days before R5020 or oil was injected. D represents systolic blood pressure values in male SHRs after administration of R5020 or oil in daily s.c. injections. Each point in each of the final groups of rats represents mean ± SEM for five rats. Means with different letters vary significantly (P <0.05). Means with at least one common superscript are not different at a value off <0.05.
rats treated with L-NAME (Molnar and Hertelendy, 1992) . The present study compares systolic blood pressure in nonpregnant and pregnant rats and identifies the existence of a blood pressure lowering mechanism during the pregnant state. This is confirmed by the observation that the blood pressure in the L-NAME treated pregnant rats becomes similar to the L-NAME treated non-pregnant rats shortly after pregnancy termination. Furthermore, the response to L-NAME is independent of the sex of the animal. The refractoriness of the blood pressure to the effects of nitric oxide synthase inhibition seen only in pregnancy is reminiscent of that described with other pressor agents (i.e. vasopressin, angiotensin, epinephrine, norepinephrine) in vivo and in vitro using human or animal models (Gant et aL, 1987) . The compensatory mechanism responsible for this refractoriness is unknown, but it probably represents a fetal and/or placental protective mechanism specific for pregnancy. To account for the findings in the rat model, this mechanism must be active during pregnancy in rats and must become deactivated just before the onset of 2780 labour. Serum progesterone concentrations increase markedly during pregnancy and drop precipitously just before the onset of labour in the rat. However, oestrogen concentrations rise abruptly before the onset of labour and peak around parturition (Puri and Garfield, 1982) during the time when blood pressure is increasing in the L-NAME-treated rats. Steroid hormones may therefore modulate vascular reactivity in the L-NAMEtreated rats. Another posssibility is that L-NAME changes the endogenous steroidogenesis. It has been suggested that NO regulates adrenal vascular tone (Cameron and Hinson, 1993) , and that, therefore, L-NAME might alter the response to stress (i.e. pump insertion, daily blood pressure measurements) and L-NAME-treated animals would develop a much higher increase in blood pressure compared with controls. However, pregnancy itself is a factor that prevents this increase, probably by improving the response to stress. Furthermore, it has been shown that L-NAME also alters the sex steroid concentrations, increasing endogenous testosterone concentrations in male rats (Welch et al., 1995) . If this is also the case during pregnancy, Figure 3 . Panel A represents systolic blood pressure in rats dunng pregnancy, with or without N^nitro-L-argirune methyl ester (L-NAME) infusions, and post-partum after injections of progesterone (P4) in a dose of 6 mg/kg/day. The L-NAME or saline osmotic pumps were inserted on day 17 (dl7) after the first blood pressure measurement. Progesterone or vehicle (sesame oil) was administered s.c. daily from post-partum day 1 (ppl) up to post-partum day 10 (pplO). Panel B represents systolic blood pressure in rats during pregnancy (with or without L-NAME infusions) and post-partum after injecuons of mifepnstone (RU486) in a dose of 30 mg/kg/day. The L-NAME or saline osmotic pumps were inserted on day 18 (dl8) after the first two blood pressure measurements. Mifepristone or vehicle (sesame oil) was administered s c daily from post-partum day 1 (ppl) up to post-partum day 10 (pplO). Each point in each of the final groups of rats represents mean ± SEM for five rats Means with different letters vary significantly (P <0 05) Means with at least one common superscnpt are not different at a value of P <0.05. -nitro-L-arginine methyl ester (L-NAME) or saline only were inserted in pregnant rats on day 17 (dl7) after the first blood pressure measurement. Levonorgestrel or sesame oil (vehicle) injections were started on the first day post-partum (ppl) and continued daily up to the 10th day post-partum (pplO). Each point in each of the final groups of rats represents mean ± SEM for five rats. Means with different letters vary significantly (P <0.05) Means with at least one common superscript are not different at a value of P <0.05. triggering a higher androgen production would result in a decrease in blood pressure in L-NAME-treated animals. This is in agreement with our conclusions that androgen administration in animals with NO blockade post-partum has a significantly hypotensive effect ( Figure 6A,B) In a prior study, we showed that in L-NAME-treated pregnant rats, progesterone prevents the rise in systolic blood pressure that occurs on the day following implantation of the L-NAME pump and on day 22, the day prior to the onset of labour (for control rats, not injected with progestin) (Buhimschi et al., 1995b) . The effect of progesterone on the post-partum increase in blood pressure could not be studied since the progesterone treatment during pregnancy prevented spontaneous labour and delivery. In the present study, we found that progesterone treatment started in the post-partum period also decreased the systolic blood pressure in the L-NAME-treated rats. This decrease is not limited to the post-partum period and is not sex specific as it was also seen in non-pregnant female and in normal male rats. It should be noted that the effect of R5020 was limited to the rats with hypertension, as the compound had no effect on the blood pressure in any of the control, normotensive, rats. The mechanism of action of R5020 in these L-NAME treated rats is not clear. It could be due to Figure 5 . Systobc blood pressure in rats during pregnancy, with or without N^-nitro-L-arginine methyl ester (L-NAME) infusions, and post-partum after injections of 17P-oestradiol (17p"E2) in a dose of 30 mg/kg/day. The L-NAME or saline osmotic pumps were inserted on day 18 (dl8) after the first two blood pressure measurements. 17{}-Oestradiol or vehicle (sesame oil) was administered s.c. daily from post-partum day 1 (ppl) up to postpartum day 10 (pplO). Each point in each of the final groups of rats represents mean ± SEM for five rats. Means with different letters vary significantly (P <0.05) Means with at least one common superscript are not different at a value of P <0.05.
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effects on blood progesterone in the whole animal as L-NAME decreases the ovarian release of progesterone (Shukovski and Tsafnri, 1994 ) and/or a direct effect of R5020 on blood vessels (Omar et ai, 1995) . If these were the reasons for the decrease in blood pressure then the effect should have been noted in the control animals also, unless the direct effect is operable only in preconstricted vessels. Another possibility is that progesterone and R5020 may have either reinstated a pathway that was blocked by L-NAME, induced an alternative compensatory pathway, or provided more substrate (arginine), making L-NAME (a competitive inhibitor) less effective. The present study also shows that from the two classes of progestagens, only the pregnane derivatives (progesterone and R5020) and not the 19-nortestosterone derivatives (like levonorgestrel) have hypotensive effects. In addition, since progesterone has also a high antimineralocorticoid activity, this could account for the decrease in blood pressure in control animals after progesterone administration. R5020, however, is a 'pure' progesterone receptor agonist devoid of any antimineralocorticoid activity (Raynaud and Ojasoo, 1983) . Levonorgestrel, on the other hand, has no mineralocorticoid or antimineralocorticoid effects (Losert et ai, 1985) , but exhibits androgenic activity, especially with higher doses (Kaplan 1995) . The hypotensive effect of testosterone on blood pressure after NO blockade seems to be due to its androgenic activity since dihydrotestosterone had similar effects. Testosterone is readily converted to oestrogens but dihydrotestosterone is not subject to conversion to oestrogen. Thus the results with testosterone do not appear to be due to any endogenous change in oestrogen concentrations.
In human pregnancy maternal serum testosterone increases significantly (1.5-fold) at the end of pregnancy. Testosterone Days Days Figure 6 . Panel A represents systolic blood pressure in rats during pregnancy, with or without N°-nitro-L-arginine methyl ester (L-NAME) infusions, and post-partum after injections of testosterone (TST) in a dose of 0.3 mg/kg/day. The L-NAME or saline osmotic pumps were inserted on day 17 (dl7) after the first blood pressure measurement. Testosterone or vehicle (sesame oil) was administered s.c. daily from post-partum day 1 (ppl) up to post-partum day 10 (pplO). Panel B represents systolic blood pressure in rats during pregnancy (with or without L-NAME infusions) and post-partum after injections of dihydrotestosterone (5cx-DHT) in a dose of 0.3 rag/kg/day. The L-NAME or saline osmotic pumps were inserted on day 18 (dl8) after the first blood pressure measurement. Dihydrotestosterone or vehicle (sesame oil) was administered s.c. daily from post-partum day 1 (ppl) up to post-partum day 10 (pplO). Each point in each of the final groups of rats represents mean ± SEM for five rats. Means with different letters vary significantly (P <0.05). Means with at least one common superscript are not different at a value of P <0.05.
concentrations are also directly correlated with the presence of a male fetus in contrast to dihydrotestosterone that exhibits a similar increase in concentrations in late compared with early pregnancy but is not correlated with the sex of the fetus either in the maternal plasma or in the amniotic fluid (Dawood and Saxena, 1977) . In rats, the concentrations of dihydrotestosterone in the peripheral circulation are high throughout pregnancy and pseudopregnancy then decreases during the lactational period. The source of dihydrotestosterone is primarily the ovary in pseudopregnant rats and the ovary plus uterus in pregnant rats (Sridaran and Gibori, 1989) . In our studies, both testosterone and dihydrotestosterone induced an elevation in blood pressure in control, normotensive rats, while significantly reducing systolic blood pressure in animals made hypertensive after NO inhibition ( Figure 6A ,B). These data seem contradictory to other data regarding the effects of androgens on blood pressure. In-vivo data advocate a prohypertensive action suggesting that androgen administration in female rats results in hypertension (Hall and Hungerford, 1982) and that gonadectomy in SHRs is followed by a decrease in blood pressure, an effect that is reversed by dihydrotestosterone (Lengsfeld et al, 1988) . In contrast, in-vitro studies suggest that testosterone has a relaxant, endothelium-independent, effect on precontracted vessels (Yue et al, 1995) . Also it has been shown that dihydrotestosterone stimulates placental progesterone production in vitro (Grimshaw et al., 1983) . Pregnancy is also associated with a shift in the baroreflex function curve to a lower operating pressure range and an attenuated ability to increase sympathetic outflow in response to a hypotensive challenge (Crandal and Heesch, 1990) . Nitric oxide has also been shown to be involved in the regulation of sympathetic tone via baroreceptor activation through interaction with the sympathetic pathway in the central nervous system (Jimbo et al, 1994) , rather than altering the afferent or efferent limbs of the baroreceptor reflex (Scrogin et al, 1994) . On the other hand both progesterone (Heesch and Rogers, 1995) and androgens (Bedran-de-Castro and Bedran-de-Castro, 1992) have been shown to modulate the baroreceptor reflex control of arterial pressure. This effect of steroid hormones on the baroreceptors is consistent with the delayed refractoriness to L-NAME treatment we noted in the pregnant rats.
Our results support the concept that progesterone and also androgens may regulate blood pressure. While the immediate regulation of blood pressure may be through the nitric oxide system, the long term refractoriness and the low systemic vascular resistance may be under the control of sex steroid hormones. There are several studies regarding the effect of steroid hormones on blood pressure. Many of these reports deal with acute treatments while others are limited to chronic administration making it difficult to generalize. Normal or abnormal blood pressure can result in altered responses to the same hormone. In our studies, most animals were treated chronically with steroids for about 10 days following L-NAME treatment. A direct effect on NO production may therefore not be apparent with NOS blockade. On the other hand, we would have been able to discern effects of steroid hormones on NOmdependent mechanisms. In our opinion the model of rats infused with L-NAME during late pregnancy and post-partum allows for a better evaluation of blood pressure changes in response to various drugs in relation with pregnancy, parturition and the rapid shift to the post-partum state. Non-pregnant, male or ovarectomized animals would be devoid of this complex environment and, as discussed above, exhibit a different response to NO blockade than pregnant rats.
Pre-eclampsia develops in ~7% of all pregnancies. It complicates up to 25% of all pregnancies in patients with underlying hypertension or chronic renal disease. The low incidence of eclampsia is due to improved antenatal care as well as early and aggressive management of severe pre-eclampsia. However, there has been a relative increase in proportion of post-partum cases of eclampsia comprising 17 to 34% of the total (Sibai et al., 1980) and it seems that the methods of detection, prevention and management of pre-eclampsia and/or eclamptic seizures in the post-partum period are still imperfect (Miles et al, 1990) . Also, some patients only develop hypertension during labour, a condition called labour onset pre-eclampsia (Long et al, 1981) . Since in humans pre-eclampsia is a disease of the third trimester with occurrences also in labour or postpartum it is possible that mechanisms that are involved in the shift of the uterine environment from the quiescent state towards labouring (i.e. steroid hormones and their antagonists, prostaglandins, nitric oxide) play some role. Many of the mediators involved in labour are known to have additional effects on vascular smooth muscle and might be responsible for changes in maternal blood pressure. Our model confirms that the penpartum period is a critical time for the development of hypertension following nitric oxide synthase blockade Because of the relatively short gestation in the rat, the nse in blood pressure may only occur a few hours before term, as opposed to days in the human pregnancy. Antepartum hormonal manipulation in the rat could therefore present some limitations. The short duration of hypertension before the onset of labour, the impracticality of lntrapartum blood pressure measurements and the inhibition of labour by progesterone in the rat precluded the antepartum use of hormones. We therefore limited the hormonal manipulation to the post-partum state, which is still an important period for the development of pre-eclampsia in humans
To summarize, this study found the following: (i) thebiphasic blood pressure response seen in pregnant rats following L-NAME treatment may be due to changing concentrations of the sex steroids that occur at term; (ii) a pregnane-derived progestin (R5020), but not a 19-nortestosterone progestin, or 17p ¥ -oestradiol, decreased blood pressure when given to rats with (postpartum, non-pregnant females and males) and without L-NAME treatment (spontaneous hypertensive male rats). This indicates that progesterone but not oestradiol may regulate blood pressure when NO synthesis is blocked; (iii) since R5020 has no antimineralocorticoid activity its blood pressure lowering effects must be mediated through other systems. The antiprogesterone RU486 further increased the blood pressure levels suggesting that progesterone's action on blood pressure is mediated through a progesterone receptor-mediated mechanism; (iv) androgens elevate blood pressure when administered in control rats post-2783
partum, but induce a sustained decrease in blood pressure when administered in the presence of NO blockade; (v) since both R5020 and androgens consistently reduced blood pressure in the presence of a NOS inhibitor, their action must be modulated through a system, or systems, acting independently of the NOcGMP pathway; (vi) progesterone and androgens may play an important role in the control of fetal perfusion and vascular adaptations during pregnancy.
